海尔生物收盘下跌1.34%，滚动市盈率28.98倍，总市值98.31亿元

Core Viewpoint - Haier Biomedical's stock closed at 30.92 yuan, down 1.34%, with a rolling PE ratio of 28.98 times, and a total market value of 9.831 billion yuan [1] Company Overview - Qingdao Haier Biomedical Co., Ltd. focuses on providing optimal user experiences for life science users, including pharmaceutical companies, research institutions, and healthcare users, forming two main business segments: life sciences and medical innovation [2] - The company offers comprehensive digital solutions represented by smart laboratories, digital hospitals, and smart public health, with key products including low-temperature storage boxes, automated biological sample storage, and various automated medication products [2] Financial Performance - In Q1 2025, the company reported revenue of 689 million yuan, a year-on-year increase of 0.30%, and a net profit of 110 million yuan, a year-on-year decrease of 19.88%, with a gross profit margin of 48.35% [3] - The company's PE ratio is significantly lower than the industry average of 48.92 times and the industry median of 35.68 times, ranking 66th in the industry [3]